Device Trial Radar · NCT05064514
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Apr 6, 2022
Primary completion
May 21, 2028
Study completion May 21, 2028
Sponsor
- Lead sponsor
- Queen Mary University of LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Royal Free Hospital NHS Foundation Trust
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.
Conditions
- Tricuspid Regurgitation
- Tricuspid Valve Disease
- Carcinoid Syndrome
- Carcinoid Heart Disease
Interventions
Transcatheter Tricuspid Valved Stent GraftDevice
All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of patients with successful implantation of the TRICENTO bioprosthesisTime frame: measured pre intervention and immediately after the intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Barts Health NHS Trust
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.